Clinical Trial Update: A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating IMC-A12 (cixutumumab) alone or in combination with antiestrogens for metastatic breast cancer has completed, with results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IMC-A12 (cixutumumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-06-06